Accessibility Menu
Merck logo

Merck(NYSE) MRK

Market Cap$323.72BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1968)+63,994%
5 Year+98%
1 Year+61%
1 Month+9%
$130.81
-0.2%
-0.26Today
Merck last closing stock price
MetricPriceDate
Last closeUSD 131.072026-07-24
Merck stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.8%USD 127.502026-07-17
1 month+8.68%USD 120.602026-06-24
3 month+17.97%USD 111.102026-04-24
Year to date+26.34%USD 103.742025-12-31
1 year+61.04%USD 81.392025-07-24
3 year+33.69%USD 98.042023-07-25
5 year+97.57%USD 66.342021-07-23
Since inception+63,994.43%USD 0.201968-01-02

Merck Financials at a Glance

Market Cap

$323.72BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$65.59B

Net Income (TTM)

$8.94B

EPS (TTM)

$3.55

P/E Ratio

36.89

Dividend

$3.36

Beta (Volatility)

0.27 (Low)

Price

$130.81

Volume

5,972,614.705

Open

$131.01

Previous Close

$130.76

Daily Range

$130.45 - $132.53

52-Week Range

$76.66 - $132.53

Estimated Earnings Date

Aug 4, 2026

MRK News

office_building_commercial_real_estate

5 Best Commercial Real Estate Stocks for 2026

Kristi WaterworthJul 16, 2026
Two people looking at a chart.

5 Best High Dividend Mutual Funds to Buy in 2026

Matt DiLalloJul 14, 2026
Doctor giving patient a vaccine shot.

6 Best Vaccine Stocks for 2026 and How to Invest

Keith SpeightsJul 13, 2026
GettyImages-941740978-1201x801-d21b45d

The Largest Healthcare Companies by Market Cap in July 2026

Lyle DalyJul 7, 2026
Pharmacists reviewing medication

5 Best GLP-1 Stocks for 2026 and How to Invest

Rachel WarrenJun 24, 2026
maxresdefault (2)

Merck: Navigating the Patent Cliff and Future Growth Prospects

Motley Fool YouTubeJun 4, 2026
Two scientists looking at a monitor showing brain scans.

Best Cancer Stocks for 2026 and How to Invest

Keith SpeightsMay 19, 2026
The word Index against a background of colored stripes

Dow Jones Industrial Average

Jeremy BowmanMay 16, 2026
Page 1

MRK: Motley Fool Moneyball Superscore

77

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Merck

Merck & Co., Inc. operates as a global healthcare company with a strong focus on pharmaceutical and vaccine innovation. The company is recognized for its significant contributions to the field of oncology, as well as its diversified product portfolio, which includes a range of vaccines, biologic therapies, and animal health products.

Products and Services

Pharmaceuticals: Notable for their blockbuster drug Keytruda, used in cancer treatment.

Vaccines: Providing immunization solutions including those for HPV and rotavirus.

Anesthesia and analgesia: Supplying medications for pain relief and sedation.

Animal Health: Offering veterinary pharmaceuticals and vaccines.

What Makes Merck & Co., Inc. Special

Merck & Co., Inc. distinguishes itself through its robust pipeline of innovative products across multiple therapeutic areas. Their focus on oncology, vaccines, and rare diseases, alongside a strategic approach to research and development, supports its competitive advantage. Additionally, the company’s operational efficiency and strategic global market expansions contribute to its resilience and growth potential.

Five Things You Need to Know

Keytruda is a leading cancer treatment driving the company's revenue growth.

The company has a strong pipeline with 20 potential growth drivers.

Merck maintains substantial gross margins which support reinvestment and cash flow.

The company is expanding into international markets like China and Europe.

Potential challenges include patent expirations and biosimilar competition.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

75,000

CEO

Robert M. Davis, MBA

Website

www.merck.com

Headquarters

Rahway, NJ 07065, US

MRK Financials

Key Financial Metrics (TTM)

Gross Margin

75.91%

Operating Margin

27.59%

Net Income Margin

13.62%

Return on Equity

17.93%

Return on Capital

22.77%

Return on Assets

6.94%

Earnings Yield

2.71%

Dividend Yield

2.56%

Payout Ratio

92.12%

Stock Overview

Market Cap

$323.72BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.47B

Volume

5.97M

Avg. Volume

10.28M

Financials (TTM)

Gross Profit

$49.79B

Operating Income

$18.10B

EBITDA

$18.78B

Operating Cash Flow

$17.89B

Capital Expenditure

-$3.78B

Free Cash Flow

$14.12B

Cash & ST Invst.

$5.70B

Total Debt

$49.12B

Merck Performance Analysis

Merck annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 58,473,000,00019.6%
20232023-12-31USD 59,871,000,0002.4%
20242024-12-31USD 63,973,000,0006.9%
20252025-12-31USD 64,926,000,0001.5%
Merck sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-301.2%
Q32025-09-308.8%
Q42025-12-31-5.0%
Q12026-03-31-0.2%
Merck annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 5.7111.1%
20232023-12-31USD 0.14-97.5%
20242024-12-31USD 6.744600.8%
20252025-12-31USD 7.288.1%
Merck sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-12.4%
Q32025-09-3031.8%
Q42025-12-31-48.7%
Q12026-03-31-244.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$16.29B

+4.3%

Gross Profit

$13.34B

+13.7%

Gross Margin

81.92%

N/A

Market Cap

$323.72BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.32M

N/A

Employees

75,000

N/A

Net Income

-$4.24B

-183.5%

EBITDA

-$2.02B

-127.6%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$5.70B

-38.2%

Total Debt

$49.12B

+41.0%

Accounts Receivable

$12.21B

+13.2%

Inventory

$6.48B

+4.6%

Long Term Debt

$46.67B

+39.4%

Short Term Debt

$2.44B

+79.7%

Return on Assets

6.94%

N/A

Return on Invested Capital

17.79%

N/A

Free Cash Flow

$2.93B

+149.7%

Operating Cash Flow

$3.92B

+56.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NVSNovartis AG
$156.11+0.71%
NVONovo Nordisk A/S
$49.67+1.85%
TMOThermo Fisher Scientific Inc.
$559.53-1.54%
AMGNAmgen Inc.
$376.26+0.06%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%
TAT&T
$24.42+0.01%

Questions About MRK

What is the current price of Merck?

Merck is trading at $130.76 per share.

What is the 52-week range for Merck?

Over the past 52 weeks, Merck has traded between $76.66 and $132.53.

How much debt does Merck have?

As of the most recent reporting period, Merck reported total debt of $49.12B.

How much cash does Merck have on hand?

Merck reported $5.40B in cash and cash equivalents in its most recent financial results.

What is Merck’s dividend yield?

Merck currently has a dividend yield of 2.56%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services